These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 29903674)

  • 41. Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged ≥2 years: an open-label study.
    Cordonnier C; Ljungman P; Juergens C; Maertens J; Selleslag D; Sundaraiyer V; Giardina PC; Clarke K; Gruber WC; Scott DA; Schmoele-Thoma B;
    Clin Infect Dis; 2015 Aug; 61(3):313-23. PubMed ID: 25870329
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations.
    Parikh R; Widenmaier R; Lecrenier N
    Expert Rev Vaccines; 2021 Sep; 20(9):1065-1075. PubMed ID: 34311643
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis.
    McGirr A; Widenmaier R; Curran D; Espié E; Mrkvan T; Oostvogels L; Simone B; McElhaney JE; Burnett H; Haeussler K; Thano A; Wang X; Newson RS
    Vaccine; 2019 May; 37(22):2896-2909. PubMed ID: 30982636
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine.
    Glesby MJ; Watson W; Brinson C; Greenberg RN; Lalezari JP; Skiest D; Sundaraiyer V; Natuk R; Gurtman A; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    J Infect Dis; 2015 Jul; 212(1):18-27. PubMed ID: 25395187
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.
    De Montalembert M; Abboud MR; Fiquet A; Inati A; Lebensburger JD; Kaddah N; Mokhtar G; Piga A; Halasa N; Inusa B; Rees DC; Heath PT; Telfer P; Driscoll C; Al Hajjar S; Tozzi A; Jiang Q; Emini EA; Gruber WC; Gurtman A; Scott DA
    Pediatr Blood Cancer; 2015 Aug; 62(8):1427-36. PubMed ID: 25810327
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.
    Bhorat AE; Madhi SA; Laudat F; Sundaraiyer V; Gurtman A; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    AIDS; 2015 Jul; 29(11):1345-54. PubMed ID: 25888646
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal non-typeable Hemophilus influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with the DTPw-HBV/Hib vaccine in Indian infants: a single-blind, randomized, controlled study.
    Lalwani S; Chatterjee S; Chhatwal J; Verghese VP; Mehta S; Shafi F; Borys D; Moreira M; Schuerman L
    Hum Vaccin Immunother; 2012 May; 8(5):612-22. PubMed ID: 22634448
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial.
    Hata A; Inoue F; Hamamoto Y; Yamasaki M; Fujikawa J; Kawahara H; Kawasaki Y; Honjo S; Koshiyama H; Moriishi E; Mori Y; Ohkubo T
    Diabet Med; 2016 Aug; 33(8):1094-101. PubMed ID: 26605507
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old.
    MacIntyre CR; Egerton T; McCaughey M; Parrino J; Campbell BV; Su SC; Pagnoni MF; Stek JE; Xu J; Annunziato PW; Chan IS; Silber JL
    Hum Vaccin; 2010 Nov; 6(11):894-902. PubMed ID: 20980796
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised study.
    Cutland CL; Nolan T; Halperin SA; Kurugol Z; Ahmed K; Perrett KP; Richmond P; Marshall HS; Ceyhan M; Kolhe D; Hezareh M; Van Der Wielen M
    Vaccine; 2018 Mar; 36(14):1908-1916. PubMed ID: 29503112
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Randomized controlled study of the safety and immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified pneumolysin with alum or adjuvant system AS02V in elderly adults.
    Pauksens K; Nilsson AC; Caubet M; Pascal TG; Van Belle P; Poolman JT; Vandepapelière PG; Verlant V; Vink PE
    Clin Vaccine Immunol; 2014 May; 21(5):651-60. PubMed ID: 24599529
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunogenicity and Safety of Adjuvanted Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients on Anti-Cellular Biologic Agents or JAK Inhibitors: A Prospective Observational Study.
    Venerito V; Stefanizzi P; Cantarini L; Lavista M; Galeone MG; Di Lorenzo A; Iannone F; Tafuri S; Lopalco G
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108130
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age.
    Chlibek R; Bayas JM; Collins H; de la Pinta ML; Ledent E; Mols JF; Heineman TC
    J Infect Dis; 2013 Dec; 208(12):1953-61. PubMed ID: 23904292
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunologic non-inferiority and safety of the investigational pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) 4-dose vial presentation compared to the licensed PHiD-CV 1-dose vial presentation in infants: A phase III randomized study.
    Zaman K; Zaman SF; Zaman F; Aziz A; Faisal SB; Traskine M; Habib MA; Ruiz-Guiñazú J; Borys D
    Vaccine; 2018 Jan; 36(5):698-706. PubMed ID: 29277353
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial.
    Schmader KE; Levin MJ; Grupping K; Matthews S; Butuk D; Chen M; Idrissi ME; Fissette LA; Fogarty C; Hartley P; Klein NP; Nevarez M; Uusinarkaus K; Oostvogels L; Curran D
    J Gerontol A Biol Sci Med Sci; 2019 Jul; 74(8):1217-1224. PubMed ID: 30256905
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine.
    Pirrotta P; Tavares-Da-Silva F; Co M; Lecrenier N; Hervé C; Stegmann JU
    Drug Saf; 2021 Dec; 44(12):1341-1353. PubMed ID: 34622421
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study.
    Iwata S; Kawamura N; Kuroki H; Tokoeda Y; Miyazu M; Iwai A; Oishi T; Sato T; Suyama A; François N; Shafi F; Ruiz-Guiñazú J; Borys D
    Hum Vaccin Immunother; 2015; 11(4):826-37. PubMed ID: 25830489
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses.
    Kawakami K; Kishino H; Kanazu S; Toshimizu N; Takahashi K; Sterling T; Wang M; Musey L
    Vaccine; 2016 Jul; 34(33):3875-81. PubMed ID: 27265450
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: A phase III, randomized study.
    Dbaibo G; Tinoco Favila JC; Traskine M; Jastorff A; Van der Wielen M
    Vaccine; 2018 Jun; 36(28):4102-4111. PubMed ID: 29784470
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety, tolerability and immunogenicity of 15-valent pneumococcal conjugate vaccine in toddlers previously vaccinated with 7-valent pneumococcal conjugate vaccine.
    Sobanjo-ter Meulen A; Vesikari T; Malacaman EA; Shapiro SA; Dallas MJ; Hoover PA; McFetridge R; Stek JE; Marchese RD; Hartzel J; Watson WJ; Musey LK
    Pediatr Infect Dis J; 2015 Feb; 34(2):186-94. PubMed ID: 25741971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.